Skip to main content

Table 1 Breast cancer risk in relation to CYP17 genotype, stratified by breast cancer risk factors

From: CYP17 gene polymorphism in relation to breast cancer risk: a case-control study

 

All genotypes

CYP17 genotype

P for interaction

   

A1/A1

A1/A2

A2/A2

 
 

Cases/controlsa

ORb (CI)

Cases/controlsa

ORb (CI)

Cases/controlsa

ORb (CI)

Cases/controlsa

ORb (CI)

 

Age at menarche (years)

         

≤12

314/262

1 (reference)

102/96

1 (reference)

138/128

1.1 (0.7–1.5)

74/38

1.9 (1.1–3.0)

 

>12–14

749/702

0.9 (0.7–1.1)

283/251

1.1 (0.8–1.5)

360/325

1.1 (0.8–1.5)

106/126

0.8 (0.6–1.0)

 

>14

300/258

1.0 (0.8–1.2)

107/94

1.1 (0.7–1.6)

152/126

1.2 (0.8–1.7)

41/38

1.1 (0.6–1.8)

0.026

Age at menopause (years)

         

<49

330/347

1 (reference)

145/123

1 (reference)

141/165

0.7 (0.5–1.0)

44/59

0.7 (0.4–1.1)

 

49–52

802/656

1.3 (1.1–1.6)

282/243

1.0 (0.7–1.3)

380/316

1.0 (0.8–1.4)

140/97

1.2 (0.9–1.8)

 

>52

357/323

1.2 (1.0–1.5)

119/117

1.0 (0.6–1.3)

184/150

1.1 (0.8–1.6)

54/56

0.8 (0.5–1.3)

0.062

Age at first birth (years)

         

≤24

616/639

1 (reference)

225/236

1 (reference)

310/315

1.1 (0.8–1.3)

81/88

1.0 (0.7–1.4)

 

25–29

414/388

1.1 (0.9–1.4)

145/144

1.1 (0.8–1.5)

187/171

1.2 (0.9–1.6)

82/73

1.2 (0.8–1.7)

 

≥30

242/187

1.4 (1.1–1.7)

100/67

1.6 (1.1–2.3)

107/89

1.3 (0.9–1.8)

35/31

1.1 (0.7–1.9)

0.752

Parity

         

Nulliparous

224/124

1 (reference)

79/41

1 (reference)

105/63

0.9 (0.5–1.5)

40/20

1.2 (0.6–2.3)

 

1 child

320/240

0.7 (0.5–0.9)

113/77

0.8 (0.5–1.2)

168/130

0.7 (0.4–1.0)

39/33

0.6 (0.3–1.1)

 

2 children

569/515

0.6 (0.4–0.7)

215/195

0.6 (0.4–0.9)

254/238

0.5 (0.4–0.8)

100/82

0.6 (0.4–1.0)

 

>2 children

386/459

0.5 (0.4–0.6)

143/175

0.4 (0.3–0.7)

184/207

0.5 (0.3–0.7)

59/77

0.4 (0.2–0.6)

0.792

Body mass index (kg/m2)

         

<25

716/669

1 (reference)

263/230

1 (reference)

337/329

0.9 (0.7–1.2)

116/110

0.9 (0.7–1.3)

 

25 to <28

371/377

1.0 (0.8–1.1)

141/137

0.9 (0.7–1.2)

170/181

0.9 (0.7–1.2)

60/59

0.9 (0.6–1.4)

 

≥28

403/278

145/116

1.2 (0.9–1.6)

198/121

1.4 (1.1–1.9)

60/41

1.4 (0.9–2.2)

0.657

 
  1. aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. bAnalyses were conditioned on age (5-year age groups), menopausal estrogen only use (never, <4 years or ≥4 years), use of estrogen in combination with progestin (never, <4 years or ≥4 years) and diabetes mellitus (yes or no). CI, confidence interval; OR, odds ratio.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us